LifeSci Capital Initiates Coverage of SciClone

Profitable Specialty Pharmaceutical Company with Steady Revenue Growth; Report Available here: http://www.lifescicapital.com/equity-research/sciclone/

NEW YORK, NY / ACCESSWIRE / March 8, 2015 / LifeSci Capital, LLC, a research-driven investment bank with deep domain expertise in the life sciences sector, today announced that it has initiated coverage of SciClone (NASDAQ: SCLN), a profitable specialty pharmaceutical company that develops and commercializes products in the growing Chinese market. The Company’s lead product and main source of revenue is Zadaxin (thymalfasin), an immune system enhancer used in the treatment of cancer and hepatitis. Zadaxin sales increased by an estimated 16% from 2014 to 2015, and have the potential to continue growing as the Chinese pharmaceutical market expands.

Zadaxin is a high quality, imported version of thymalfasin that is used as an immune system enhancer for patients with cancer and hepatitis. Many Chinese physicians and patients strongly prefer imported products as long as the patients can afford them. There is a belief that locally manufactured products are poor quality, even ones that are produced at GMP-certified facilities. In addition to selling wholly-owned Zadaxin and DC Bead, which was launched in 2015, the team also markets 6 products as part of promotion agreements with Baxter (NYSE: BAX) and Pfizer (NYSE: PFE). SciClone has guided revenues for 2015 of $157 to $158 million, which would be a 17% increase over 2014. Net income in 2014 was $25.2 million, derived from revenue of $132 million.

In a 29 page Initiation Report LifeSci Capital explains the Chinese pharmaceutical market and how SciClone’s products fit within the changing landscape. The report also discusses SciClone’s pipeline of 7 in-licensed products that are in various stages of clinical development and that are expected to drive long-term revenue growth.

Dr. Isaacson’s full Initiation Report, including important disclosures, is available to download at no cost at the LifeSci Capital website, www.lifescicapital.com/equity-research/. In addition to this Initiation Report, LifeSci Capital intends to provide ongoing coverage and event-based research updates on SciClone as developments occur.

The LifeSci Capital research team is led by Dr. Jerry Isaacson, an industry veteran with broad experience in biotechnology, having worked in both public and private biotech companies in areas ranging from medicinal chemistry and analytical chemistry to patents and investor/public relations. Dr. Isaacson holds a Bachelor of Arts degree in Chemistry from Harvard University and received his Ph.D. in Organic Chemistry from the University of California in San Diego.

About LifeSci Capital:

LifeSci Capital (Member: FINRA/SIPC) is a research-driven investment bank with deep domain expertise in the life sciences. Our service model as a boutique investment bank is unique in that we exclusively serve emerging life science companies that discover, develop, and commercialize innovative products. We view our clients as our partners, and we work closely with them to establish and execute their capital markets strategies. Our broadly-distributed equity research product is differentiated and provides a deep understanding of our clients’ businesses and the opportunities they are addressing. To learn more about LifeSci Capital, visit the company’s website, www.lifescicapital.com.

Analyst Contact:

Jerry Isaacson, Ph.D.
Phone: (646) 597-6991
Email: jisaacson@lifescicapital.com

SOURCE: LifeSci Capital

ReleaseID: 437609